Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites
Clinical trial NCT01978236 · TERMINATED
Trial details
- NCT number
- NCT01978236
- Sponsor
- GlaxoSmithKline
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-04-08
- Primary completion
- 2017-04-26
- Enrollment
- 6
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.